Company Overview and News

0
Blue Sky Uranium Oversubscribed - Company Closes Final Tranche of Non-Brokered Private Placement

2018-06-14 globenewswire
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSXV:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to announce it has closed the final tranche of the non-brokered private placement financing announced on June 1, 2018 and increased on June 4, 2018 consisting of 1,428,572 units in this tranche for a total of 24,906,588 units at a price of $0.
BSK BKUCF

0
Blue Sky Uranium Oversubscribed - Company Closes Non-Brokered Private Placement

2018-06-12 globenewswire
VANCOUVER, British Columbia, June 12, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to announce it has closed the first tranche of the non-brokered private placement financing announced on June 1, 2018 and increased on June 4, 2018 consisting of 23,479,016 units at a price of $0.14 per unit for gross proceeds of $3,287,062.
BSK BKUCF

0
Blue Sky Uranium Increases Non-Brokered Private Placement

2018-06-04 globenewswire
VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") announces that due to high investor demand, the Company has increased the private placement amount announced on June 1, 2018 from $2,660,000 to $3,080,000 consisting of 22 million units (the “Units”) at $0.14 per Unit.
BSK BKUCF

0
Blue Sky Uranium Announces

2018-06-04 globenewswire
VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is a member of the Grosso Group and is the 100% owner of approximately 459,000 hectares (1,134,000 acres) of uranium and vanadium concessions in Argentina in the southern provinces of Chubut and Río Negro, Argentina.
BSK BKUCF

0
Blue Sky Uranium Announces Non-Brokered Private Placement

2018-06-01 globenewswire
VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to announce a non-brokered private placement financing of up 19,000,000 units at a price of $0.14 per unit for gross proceeds of $2,660,000. Current shareholders have expressed interest to acquire a significant majority of this financing.
BSK BKUCF

0
Blue Sky Uranium Reports Positive Concentration Tests for Uranium and Vanadium at Amarillo Grande Project, Argentina

2018-05-23 globenewswire
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to report that the initial process testing on oxide material from the Company’s Ivana uranium-vanadium deposit demonstrated that simple wet scrubbing followed by wet screening results in the upgrading of metal concentration by approximately 300% for Uranium and 250% for Vanadium.
BSK BKUCF

0
Blue Sky Uranium (BKUCF) Presents At International Mining Investment Conference - Slideshow

2018-05-16 seekingalpha
The following slide deck was published by Blue Sky Uranium Corp. in conjunction with this event.
BSK BKUCF

13
Expert Uranium Metallurgist Joins Blue Sky Uranium Team as it Advances Amarillo Grande Uranium-Vanadium Project, Argentina

2018-05-09 globenewswire
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to report it has engaged Chuck Edwards P.Eng. as a technical advisor to assist the Company in planning and managing beneficiation (upgrading) and metallurgical studies and process design for the Ivana Uranium-Vanadium deposit and the Amarillo Grande project.
AMFW BSK BKUCF AMCBF AMFW CCJ

0
Blue Sky Uranium Files NI 43-101 Technical Report for the First Mineral Resource Estimate at Amarillo Grande Uranium-Vanadium Project, Argentina

2018-04-18 globenewswire
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF), ("Blue Sky" or the "Company") is pleased to announce that the Company has filed the NI 43-101 Technical Report (the “Report”) supporting disclosure of the initial independent mineral resource estimate for the Ivana Deposit at the Company’s 100% owned Amarillo Grande Uranium-Vanadium Project in Rio Negro Province, Argentina, as reported on March 5th, 2018.
BSK BKUCF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...